2014

Bispecific Antibody Therapeutics Market, 2013 - 2023

NEW YORK, Oct. 2, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Bispecific Antibody Therapeutics Market, 2013 - 2023

http://www.reportlinker.com/p01658507/Bispecific-Antibody-Therapeutics-Market-2013---2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

 

Antibody based therapeutics are the fastest growing segment of the drugs and biologics market. There are 30 approved antibody based therapeutics available in the US and European markets since the launch of first anti-CD3 antibody, Orthoclone Okt3, in 1986.

 

A bispecific antibody is a second generation immunotherapy, an upgraded version of monoclonal antibody improved in structure and functionality. The conjugated artificial antibodies are formed by physically putting together two monoclonal antibodies (or parts of) which have different binding specificities. This results in a combination antibody that has simultaneous functional binding affinities to two or three different epitopes. The combination may have additive and sometimes even a synergistic effect in combating a disease.

 

With the EMA approval for Removab in 2009, a great deal of interest has been generated in the bispecific antibody market. The pipeline is rich and diverse, with drugs being developed for both oncological and non-oncological indications. The industry has drugs in phase I and phase II of clinical trials but currently lacks drugs in phase III.

 

The "Bispecific Antibody Therapeutics Market, 2013-2023" report extensively studies the current and upcoming market of the bispecific antibodies for therapeutic use. This new class of antibody based therapeutics are likely to help target and combat multifactorial diseases through their potential to bind two antigens simultaneously.

 

Synopsis

 

The report covers bispecific antibody drugs currently available in the market as well as in various stages of clinical trials. It highlights various companies which are active in the market and discusses, in detail, the technologies which form the basis of many of the pipeline drugs.

 

Expecting more FDA and EMA approvals of bispecific antibodies in the coming years, one of the key objectives of this report is to forecast the size of this market over the course of next ten years. This is done by analysing:

Molecules in pipeline and drugs approved for marketing across various geographical regions

Research programs, focused on bispecific antibody therapeutics, of global pharmaceutical companies and recently established start-ups

Technologies to produce bispecific antibodies

Likely adoption rate of the new drugs, some of which are expected to be used for lifecycle management of existing drugs

 

The report provides short-mid term and long term market forecasts for the period 2013 - 2018 and 2018 - 2023, respectively. We have discussed, in detail, the key drivers behind the growth of this market. The research, analysis and insights presented in this report include the sales of eight marketed and pipeline bispecific antibodies. Owing to niche nature of the market, with most products in the pipeline, we provide three scenarios for our market forecast to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of market evolution. The figures mentioned in this report are in USD, unless otherwise specified.

 

Example Highlights

 

Oncology dominates the field of bispecific antibodies. Many drugs are in Phase I and II clinical trials while one drug, Removab, has already received approval for marketing.

The market covers both big and small pharmaceutical firms. Some big pharmaceutical companies active in the market include, but not limited to, Roche, AbbVie, Pfizer, Sanofi, Amgen, GSK, Bayer, and Merck.

Each of the pipeline drugs are being tested for several indications. This one drug- multiple applications prospect is extremely appealing to drug manufactures as it reduces their development costs and increases chances of creation of drugs for many diseases at once.

By 2023, we estimate the market to be worth USD 4.4 billion. The ongoing evolution of technology platforms and increased venture capital interest will act as strong enablers to support the growth of this market.

Owing to the complexity of the structure of bispecific antibodies, there are abundant opportunities for contract manufacturers in this area. In particular, the purification of bispecific antibodies is a challenging task, making this field attractive for contract manufacturers and purification technology providers.

There are opportunities for the large pharmaceutical companies to either in-license the technology or the product. Companies can develop innovative molecules in-house using in-licensed technology or collaborate on the development of a product already in clinical development to expand their portfolio of drugs.

 

Research Methodology

 

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

 

The secondary sources of information include

Annual reports

Investor presentations

SEC filings

Industry databases

News releases from company websites

Government policy documents

Other analysts' opinion reports

 

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

 

Chapter Outlines

 

Chapter 2 provides a general introduction to the concept of bispecific antibodies, covering basics such as antibody technology, the conventional monoclonal antibody and its comparison with bispecific antibody. The chapter also highlights the historic evolution of the industry since the launch of first anti-CD3 antibody, Orthoclone Okt3, in 1986.

 

Chapter 3 provides a detailed overview and background of the bispecific antibodies market. This chapter covers a detailed pipeline analysis of various molecules under preclinical and clinical trials. We have segmented the drugs on the basis of respective technologies and indications.

 

Chapter 4 analyses the commercial potential of the global bispecific antibody market, with a special emphasis on the future growth over the next ten years. The market forecast is based on the evolution of the current marketed drug (Removab) and the likely adoption of various drugs which are in advanced clinical trial stages.

 

Chapter 5 focuses on the various technology platforms currently available or being developed for bispecific antibody production. The chaper highlights many companies which are active in the bispecific antibody market either as drug developers and / or technology providers. We have profiled, in detail, the most promising technologies which form the basis of upcoming pipeline drugs. In addition, this chapter also provides details on the recent partnerships which have emerged in this field.

.

Chapter 6 provides profiles of the key companies in the bispecific antibody market. Each company profile includes information such as financial performance, geographical presence, marketed / pipeline drugs and recent developments.

 

Chapter 7 analyses the various factors impacting the global bispecific antibody market under the SWOT framework. We examine the various technological, commercial and regulatory trends which have shaped the industry till date.

 

Chapter 8 concludes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

 

Chapter 9 is the appendix, which lists all the companies and organisations mentioned in this report.

 

Chapter 10 is the appendix, which provides tabulated data and numbers for all the figures provided in the report.

1. EXECUTIVE SUMMARY

1.1. Scope of the Report

1.2. Research Methodology

1.3. Chapter Outlines

1.4. Key Highlights

1.4.1. Removab is the Only Approved and Marketed Bispecific Antibody

1.4.2. Bispecific Antibodies are being Developed for Both Oncological and Non-oncological Indications

1.4.3. Big Pharma and Small Pharma are Equally Involved in the Market

1.4.4. Future Market Potential

1.4.5. BiTE and Triomab Technologies are the Backbone of Most Pipeline Drugs

1.4.6. Strengths Overcome Weaknesses

 

2. INTRODUCTION

2.1. Chapter Overview

2.2. Immunotherapy: Antibody Ammunitions

2.3. Antibody Based Therapeutics

2.3.1. Ten of the Approved Antibody Based Therapeutics are Non-Canonical

2.3.2. Dominance of Antibody Based Therapeutics

2.4. Structure of an Antibody

2.5. Monoclonal Antibodies v/s. Bispecific Antibodies

2.5.1. Monoclonal Antibodies

2.5.2. Bispecific Monoclonal Antibody

2.5.3. The Bispecific Advantage

2.6. Bispecific Antibody Formats

2.7. Evolution Of Bispecific Antibodies

2.7.1. First Generation Bispecific Antibodies

2.7.1.1. Triomabs: Made Using Hybridomas / Quadromas

2.7.1.2. Shortcoming of First Generation Bispecific Antibodies

2.7.2. Second Generation Bispecific Antibodies

2.7.2.1. Tandem Single-chain Variable Fragment (scFv)

2.7.2.2. Diabodies

2.7.2.3. Two-in-one antibody

2.7.2.4. Dual Variable Domain Antibodies (DVD-Ig)

2.7.2.5. Shortcoming Of Recombinant Bispecific Antibodies

2.8. Types Of Bispecific Antibodies by Mode of Action

2.8.1. T Cell Engagement

2.8.2. Pre-targeting Systems

2.8.3. Ligand Neutralisation And Cross Linking Of Receptors System

2.9. Companies Active In The Market

 

3. MARKET OVERVIEW AND PIPELINE OF BISPECIFIC ANTIBODIES

3.1. Introduction

3.2. Drugs Indicated for Oncological Diseases

3.3. Drugs Indicated For Non-Oncological Diseases

3.4. Drugs In Preclinical Trials

3.5. Analysis of the Pipeline

3.5.1. Drugs Are Spread In Phase I And Phase II Of Clinical Trials

3.5.2. Most Drugs Deploy Use of the T Engager Cell Mechanism Using CD3 Antigen Recognition

3.5.3. Pipeline Dominated by Drugs Indicated for Oncological Diseases

3.5.3.1. Focus on Solid Tumor

3.5.4. Companies With the Most Active Pipeline

 

4. CURRENT MARKET AND FORECAST

4.1. Introduction

4.1.1. Scope and Limitations

4.1.2. Assumptions For Market Forecast

4.2. Overall Bispecific Antibodies Market

4.2.1. Overall Bispecific Antibodies Market Forecast: Short-Midterm, 2013 - 2018

4.2.2. Overall Bispecific Antibodies Market Forecast: Long Term, 2018 - 2023

4.3. Catumaxomab / Removab (Fresenius Biotech, Trion Pharma, Neopharm)

4.3.1. Drug Overview

4.3.2. Removab: Structure and Mechanism of action

4.3.3. Orphan Drug Designations for Removab

4.3.4. Geographical Presence

4.3.5. Cost of Removab

4.3.6. Current Status of Development

4.3.7. Removab Sales (2011 - Q1 2013)

4.3.8. Reimbursement for Removab

4.3.9. Market Opportunity In Cancer Associated Malignant Ascites

4.3.10. Catumaxomab / Removab Sales Forecast: Short-Mid Term, 2013 - 2018

4.3.11. Catumaxomab / Removab Sales Forecast: Long Term, 2018 - 2023

4.4. Duligotumab / MEHD7945A / RG7597 (Roche / Genentech)

4.4.1. Overview

4.4.2. Structure and Mechanism of Action

4.4.3. Current Status of Development

4.4.4. Competition for Duligotumab

4.4.5. Duligotumab / MEHD7945A / RG7597 Sales Forecast: Long Term, 2018 - 2023

4.5. PF-04382923 / RN6G (Pfizer)

4.5.1. Overview

4.5.2. Mechanism of Action

4.5.3. Current Status of Development

4.5.4. Dry AMD: An Attractive Opportunity

4.5.5. PF-04382923 / RN6G Sales Forecast: Long Term, 2018 - 2023

4.6. SAR156597 (Sanofi)

4.6.1. Drug Specifications

4.6.2. Mechanism of Action

4.6.3. Orphan Drug Status

4.6.4. Idiopathic Pulmonary Fibrosis: An Attractive Opportunity

4.6.5. Current Status of Development

4.6.6. SAR156597 Sales Forecast: Short-Mid Term, 2013 - 2018

4.6.7. SAR156597 Sales Forecast: Long Term, 2018 - 2023

4.7. Ozoralizumab / ATN 103 (Ablynx)

4.7.1. Drug Specifications

4.7.2. Mechanism of Action

4.7.3. Highs and Lows of Development

4.7.4. Competition for Ozoralizumab

4.7.5. Current Ongoing Trials

4.7.6. Ozoralizumab / ATN 103 Sales Forecast: Long Term, 2018 - 2023

4.8. ALX-0061 (Ablynx)

4.8.1. Drug Specifications

4.8.2. Mechanism of Action

4.8.3. Desirable Features of ALX-0061

4.8.4. Current Status of Development

4.8.5. Competiton for ALX-0061

4.8.6. ALX-0061 Sales Forecast: Long Term, 2018 - 2023

4.9. MM-111 (Merrimack Pharmaceuticals)

4.9.1.1. Drug Specifications

4.9.1.2. Mechanism of Action

4.9.2. Recent Developments

4.9.2.1. Current Development Status

4.9.3. Potential in Patients With Moderate Her2 Expression

4.9.4. MM-111 Sales Forecast: Long Term, 2018 - 2023

4.10. Blinatumomab / MT 103 / MEDI 538 / AMG 103 (AMGEN)

4.10.1. Drug Specifications

4.10.2. Mechanism of Action

4.10.3. Amgen's Addition To Its Pipeline

4.10.4. Orphan Drug Designation

4.10.5. Current Development Status

4.10.6. Competitor Drugs

4.10.7. Blinatumomab / MT 103 / MEDI 538 / AMG 103 Sales Forecast: Short-Mid Term, 2013 - 2018

4.10.8. Blinatumomab / MT 103 / MEDI 538 / AMG 103 Sales Forecast: Long Term, 2018 - 2023

4.11. OTHER PIPELINE DRUGS

4.11.1. CD20Bi / FBT-A05 / Lymphomun (Fresenius Biotech) – investigator-sponsored trials

4.11.1.1. Drug Specifications and Mechanism of action

4.11.1.2. Current Development Status

4.11.2. TF2 (Immunomedics) – pretargeting imaging and radioimmunotherapy agent

4.11.2.1. Drug Specifications

4.11.2.2. Mechanism of action

4.11.2.3. Current Development Status

4.11.3. Ertumaxomab/Rexomun (Fresenius Biotech) – phase 2 terminated

4.11.3.1. Drug Specifications

4.11.3.2. Current Development Status

 

5. TECHNOLOGY PLATFORMS

5.1. Introduction

5.2. Bispecific Antibody Production: Technology Providers And Available Technologies

5.3. Promising Technologies

5.3.1. Triomab / Quadroma (Trion Pharma)

5.3.1.1. The Technology

5.3.1.2. Drugs Based On Triomab

5.3.1.3. Pharmaceutical Companies Showing Interest in the Technology

5.3.2. Tribody technology (Biotecnol)

5.3.2.1. The Technology

5.3.2.2. Drugs Based On Tribody

5.3.2.3. Pharmaceutical Companies Showing Interest In The Technology

5.3.2.4. Advantages Of Tribody Technology

5.3.3. Bispecific T Cell Engager / BiTE (Amgen)

5.3.3.1. The Technology

5.3.3.2. Drugs Based on BiTE

5.3.3.3. Pharmaceutical Companies Showing Interest in the Technology

5.3.3.4. Advantages Of BiTE Technology

5.3.4. DART (MacroGenics)

5.3.4.1. The Technology

5.3.4.2. Drugs Based On DART

5.3.4.3. Pharmaceutical Companies Showing Interest In The Technology

5.3.4.4. Advantages of DART

5.3.5. DuoBody (Genmab)

5.3.5.1. The Technology

5.3.5.2. Pharmaceutical Companies Showing Interest In The Technology

5.3.5.3. Advantages Of DuoBody Technology

5.3.6. TandAb (Affimed)

5.3.6.1. The Technology

5.3.6.2. Mode of Action

5.3.6.3. Drugs Based on TandAb

5.3.6.4. Advantages Of TandAb Technology

5.3.7. DVD-Ig (AbbVie)

5.3.7.1. The Technology

5.3.7.2. Drugs Based on DVD-Ig

5.3.7.3. Advantages Of DVD-Ig Technology

5.3.8. Nanobody (Ablynx)

5.3.8.1. The Technology

5.3.8.2. Drugs Based On Nanobody

5.3.8.3. Pharmaceutical Companies Showing Interest In The Technology

5.3.8.4. Advantages of Nanobody

5.3.9. CrossMab Technology (Roche)

5.3.9.1. The Technology

5.3.9.2. Drugs Based On CrossMab

5.3.9.3. Advantages Of CrossMab

5.3.10. Dock and Lock (Immunomedics)

5.3.10.1. The Technology

5.3.10.2. Drugs Based on DNL

5.3.10.3. Advantages Of DNL Technology

5.4. Screening and Purification Technology Companies

5.5. Pharmaceutical Company Business Models

5.5.1. Partnership / Licensing Model

5.5.2. Acquisition Model

5.5.3. In-house Model

5.6. Other Upcoming Companies and Respective Technologies

5.6.1. Paktis Antibody Services GmbH

5.6.2. Fabion Pharmaceuticals

5.6.3. Numab

5.6.4. Synimmune

5.6.5. Ambrx

5.6.6. Merus

5.7. Recent Partnerships

 

6. PROFILES OF LEADING COMPANIES

6.1. Amgen

6.1.1. Geographical Presence

6.1.2. Financial Performance

6.1.3. Technology and Pipeline Drugs

6.1.3.1. BiTE: The Proprietary Technology

6.1.3.2. Pipeline Drugs

6.2. Fresenius Biotech (now a part of Neopharm)

6.2.1. Geographical Presence

6.2.2. Financial Performance

6.2.3. Marketed and Pipeline Drugs

6.2.3.1. Removab: The Only Marketed Bispecific Antibody

6.2.3.2. Ertumaxomab

6.2.3.3. FBT-A05

6.2.4. Sale of Fresenius Biotech

6.3. Merrimack Pharmaceuticals

6.3.1. Financial Performance

6.3.2. Pipeline Drugs

6.3.2.1. MM-111

6.3.2.2. MM-141

6.4. Affimed

6.4.1. Financial Information

6.4.2. Technology and Pipeline Drugs

6.4.2.1. TandAb technology

6.4.3. Pipeline Drugs

6.5. Merus

6.5.1. Financial Information

6.5.2. Technology and Pipeline Products

6.5.2.1. Biclonics: The Proprietary Technology

6.5.2.2. Pipeline Drugs

6.6. AbbVie

6.6.1. Geographical Presence

6.6.2. Financial Performance

6.6.3. Technology and Pipeline Drugs

6.6.3.1. DVD-Ig: The Proprietary Technology

6.6.3.2. Pipeline Drugs

 

7. SWOT ANALYSIS

7.1. Overview

7.2. Strengths

7.3. Weaknesses

7.4. Opportunities

7.5. Threats

 

8. CONCLUSIONS

8.1. A Budding Market Ready to Bloom

8.2. Improvements in Purification Systems of Bispecific Antibodies is Critical

8.3. Key Driving Factors

8.4. Concluding Remarks

 

9. LIST OF COMPANIES AND ORGANISATIONS

10. TABLES

 

List of Figures

 

Figure 2.1 Number of Approved non-Canonical Antibody Based Therapeutics

Figure 2.2 Sales of Top 10 Drugs (USD MM), 2012

Figure 2.3 Parts of an Antibody

Figure 3.1 Pipeline Drugs: By Phase of Development

Figure 3.2 Pipeline Drugs: By Type of Bispecific System

Figure 3.3 Pipeline Drugs: By Indication

Figure 3.4 Oncology Bispecific Drugs: By Types of Cancer

Figure 4.1 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Base Scenario)

Figure 4.2 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Figure 4.3 Removab Quarterly Sales, 2011-2013 (EUR MM)

Figure 4.4 Malignant Ascites Market Share (%) – by Type of Cancer

Figure 4.5 Catumaxomab / Removab Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)

Figure 4.6 Catumaxomab / Removab Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Figure 4.7 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Figure 4.8 Lucentis Sales (USD MM), 2006-2012

Figure 4.9 PF-0438293 / RN6G Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Figure 4.10 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)

Figure 4.11 SAR156597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Figure 4.12 Anti-rheumatics Drug Market, 2012 - by Leading Drugs (USD MM, %)

Figure 4.13 Ozoralizumab / ATN 103 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Figure 4.14 ALX-0061 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Figure 4.15 MM-111 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Figure 4.16 Blinatumomab / MT 103 / MEDI 538 / AMG 103, Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)

Figure 4.17 Blinatumomab / MT 103 / MEDI 538 / AMG 103 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Figure 5.1 Business Models for Bispecific Antibody Therapeutic Development

Figure 6.1 Fresenius Group: Distribution of Sales, 2012

Figure 8.1 Bispecific Antibodies Market Forecast (USD MM): 2016, 2019, 2023

 

List of Tables

 

Table 2.1 Approved Antibody Based Therapeutics

Table 3.1 Oncological Bispecific Antibodies in Clinical Trials

Table 3.2 Non- Oncological Bispecific Antibodies in Clinical Trials

Table 3.3 Bispecific Antibodies in Preclinical Trials

Table 4.1 Bispecific Antibodies in Clinical Development (Phase II and Higher): Current Development Phase and Expected Launch Year

Table 4.2 Orphan Drug Designations for Removab

Table 4.3 Removab: Treatment Schedule and Cost

Table 4.4 Removab: Ongoing Clinical Trials

Table 4.5 Duligotumab / MEHD7945A / RG7597: Ongoing Clinical Trials

Table 4.6 Duligotumab / MEHD7945A / RG7597: Competitor Drug Analysis

Table 4.7 PF-04382923: Ongoing Clinical Trials

Table 4.8 Advanced Dry AMD: Some Drugs Under Development, 2013

Table 4.9 Some Drugs Under Development for Idiopathic Pulmonary Fibrosis, 2013

Table 4.10 SAR156597: Ongoing Clinical Trials

Table 4.11 Ozoralizumab / ATN 103: Ongoing Clinical Trials

Table 4.12 ALX-0061: Ongoing Clinical Trials

Table 4.13 ALX-0061: Competition Drug Analysis

Table 4.14 MM-111: Ongoing Clinical Trials

Table 4.15 Orphan Drug Designations for Blinatumomab

Table 4.16 Blinatumomab / MT 103 / MEDI 538 / AMG 103: Ongoing Clinical Trials

Table 4.17 Comparison of Blinatumomab / MT 103 / MEDI 538 / AMG 103 and SAR3419

Table 4.18 CDBi20: Ongoing Clinical Trials

Table 4.19 TF2: Ongoing Clinical Trials

Table 4.20 Rexomun: Ongoing Clinical Trials

Table 5.1 Companies Active in Bispecific Antibody Space

Table 5.2 Bispecific Antibody Technologies Platforms

Table 5.3 Drugs based on Triomab Technology

Table 5.4 Drugs based on Tribody Technology

Table 5.5 Drugs based on BiTE Technology

Table 5.6 Agreement / Partnership for BiTE Platform

Table 5.7 Drugs Based on DART

Table 5.8 Agreement / Partnership for DuoBody Platform

Table 5.9 Drugs Based on TandAb Technology

Table 5.10 Drugs Based on DVD-Ig Technology

Table 5.11 Drugs Based on Nanobody Technology

Table 5.12 Drugs Based on CrossMabTechnology

Table 5.13 Drugs Based on Dock and Lock Technology

Table 5.14 Bispecific Antibody Development: Recent Partnerships

Table 6.1 Amgen: Pipeline of Bispecific Antibodies (Phase 1 and above)

Table 6.2 Fresenius: Pipeline of Bispecific Antibodies (Phase 1 and Above)

Table 6.3 Merrimack Pharmaceuticals: Pipeline of Bispecific Antibodies (Phase 1 and Above)

Table 6.4 Affimed: Pipeline of Bispecific Antibodies

Table 6.5 Merus: Pipeline of Bispecific Antibodies

Table 6.6 Abbvie: Pipeline of Bispecific Antibodies (Phase 1 and Above)

Table 7.1 SWOT Analysis of the Bispecific Antibodies Market

Table 7.2 Contract Manufacturing Organisations with Bispecific Antibody Capabilities – Screening, Expression or Purification

Table 7.3 Companies Working to Develop IgG/Non-IgG Fusion Therapeutics

Table 10.1Approved non-Canonical Antibody Based Therapeutics

Table 10.2 Sales (USD) of top 10 drugs, 2012

Table 10.3 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Base Scenario)

Table 10.4 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Conservative Scenario)

Table 10.5 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2013 - 2018 (Optimistic Scenario)

Table 10.6 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Table 10.7 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)

Table 10.8 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)

Table 10.9 Catumaxomab / Removab Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)

Table 10.10 Catumaxomab / Removab Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Conservative Scenario)

Table 10.11 Catumaxomab / Removab Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Optimistic Scenario)

Table 10.12 Catumaxomab / Removab Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Table 10.13 Catumaxomab / Removab Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)

Table 10.14 Catumaxomab / Removab Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)

Table 10.15 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Table 10.16 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)

Table 10.17 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)

Table 10.18 PF-0438293 / RN6G Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Table 10.19 PF-0438293 / RN6G Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)

Table 10.20 PF-0438293 / RN6G Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)

Table 10.21 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)

Table 10.22 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Conservative Scenario)

Table 10.23 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2013 - 2018 (Optimistic Scenario)

Table 10.24 SAR156597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Table 10.25 SAR156597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)

Table 10.26 SAR156597 Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)

Table 10.27 Ozoralizumab / ATN 103 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Table 10.28 Ozoralizumab / ATN 103 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)

Table 10.29 Ozoralizumab / ATN 103 Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)

Table 10.30 ALX-0061 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Table 10.31 ALX-0061 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)

Table 10.32 ALX-0061 Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)

Table 10.33 MM-111 Market (USD MM), Long Term Forecast: 2018 - 2023 (Base Scenario)

Table 10.34 MM-111 Market (USD MM), Long Term Forecast: 2018 - 2023 (Conservative Scenario)

Table 10.35 MM-111 Market (USD MM), Long Term Forecast: 2018 - 2023 (Optimistic Scenario)

Table 10.36 Blinatumomab / MT 103 / MEDI 538 / AMG 103, Short-Mid Term Forecast: 2013 - 2018 (Base Scenario)

Table 10.37 Blinatumomab / MT 103 / MEDI 538 / AMG 103, Short-Mid Term Forecast: 2013 - 2018 (Conservative Scenario)

Table 10.38 Blinatumomab / MT 103 / MEDI 538 / AMG 103, Short-Mid Term Forecast: 2013 - 2018 (Optimistic Scenario)

Table 10.39 Blinatumomab / MT 103 / MEDI 538 / AMG 103, Long Term Forecast: 2018 - 2023 (Base Scenario)

Table 10.40 Blinatumomab / MT 103 / MEDI 538 / AMG 103, Long Term Forecast: 2018 - 2023 (Conservative Scenario)

Table 10.41 Blinatumomab / MT 103 / MEDI 538 / AMG 103, Long Term Forecast: 2018 - 2023 (Optimistic Scenario)

 

The following companies have been mentioned in the report.

 

Abbvie

Ablynx

Active Biotech

Acucela

Adimab

Affimed

Allergan

Allozyne

Ambrx

Amgen

Amphivena Therapeutics Inc

Baliopharm

Bayer

Beijing ABT Genetic Engineering Technology Co.

Bicycle Therapeutics

Biogen Idec

Biotecnol

BMS

Boehringer Ingelheim

Celgene

Chiome Bioscience

Chromacon

Chugai

Covagen

Dow Pharma

Dutalys

Eli Lilly

EMD Serono

Emergent

Epigen Biotech

Fabion Pharmaceuticals

FibroGen

Fresenius Biotech

F-Star

GeneNtech

Genmab

Gilead Biosciences

Goodwin Biotechnology

GSK

Imclone Systems

ImmunGene

Immunocore

Immunomedics

Intermune

Janssen

KBI Biopharma

Kyowa Hakko Kirin

Lindis Biotech

Macrogenics

Medarex

MedImmune

Merck

Meridian Life Science

Merrimack Pharmaceuticals

Merus

Micromet

Mitsubishi Tanabe

Molecular Partners AG

Novartis

Novimmune

Numab

OcellO

Oncomed

OtSuka Pharma

Paktis Antibody Services GmbH

Pfizer

PharmAbcine

Philogen

Polytherics

Receptorlogic

Regeneron

Roche

Sanofi

Santen

Servier

Shanghai Genomics

Shionogi & Co

Sutro Biopharma

Symphogen

Synimmune

Tanabe Research Labs

Trion

UCB-Celltech

X-Body Biosciences

Xencor

Zymeworks

Zymogenetics

Zyngenia

 

The following organisations have been mentioned in the report:

 

Australian Therapeutic Goods Administration

Barbara Ann Karmanos Cancer Institute

Centre René Gauducheau

EMA

FDA

French National Centre for Scientific Research

Institut National De La Santé Et De La Recherche Médicale

Nantes University Hospital

National Cancer Institute

Radboud University

Roger Williams Medical Centre

Scott and White Hospital

Technische Universität München

Université de Toulouse

University Hospital, Tuebingen

 

 

To order this report: Bispecific Antibody Therapeutics Market, 2013 - 2023

http://www.reportlinker.com/p01658507/Bispecific-Antibody-Therapeutics-Market-2013---2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

 

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.